AdipoRon's Impact on Alzheimer's Disease-A Systematic Review and Meta-Analysis

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Alzheimer's disease (AD) is a major cause of cognitive decline, marked by neurodegeneration and neuroinflammation.
• Current AD therapies face challenges due to complex pathology and limited efficacy.
• Novel therapeutic strategies are crucial for effective AD management.

Purpose of the Study:

• To evaluate AdipoRon as a potential adiponectin replacement therapy for Alzheimer's disease.
• To synthesize evidence on AdipoRon's neuroprotective effects and mechanisms in AD models.
• To identify research gaps and future directions for AdipoRon in AD treatment.

Main Methods:

• A systematic review using the PICO framework (Population, Intervention, Comparison, Outcomes).
• Inclusion of six studies (in vitro and in vivo) using various AD models (cell lines, transgenic mice).
• Assessment of outcomes including cognitive function, neuroinflammation, tau phosphorylation, and synaptic function.

Main Results:

• AdipoRon demonstrated potential neuroprotective effects across different AD models.
• Evidence suggests AdipoRon can reduce neuroinflammation and tau hyperphosphorylation.
• Improvements in mitochondrial function and synaptic deficiencies were observed.

Conclusions:

• AdipoRon exhibits promising therapeutic potential for Alzheimer's disease.
• Adiponectin receptor agonism offers a novel mechanism for AD intervention.
• Further research is warranted to explore clinical applications and optimize AdipoRon-based therapies.